Biomarkers for Myocarditis and Inflammatory Cardiomyopathy.


Journal

Current heart failure reports
ISSN: 1546-9549
Titre abrégé: Curr Heart Fail Rep
Pays: United States
ID NLM: 101196487

Informations de publication

Date de publication:
10 2022
Historique:
accepted: 20 07 2022
pubmed: 2 8 2022
medline: 12 10 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

Myocarditis is a disease caused by inflammation of the heart that can progress to dilated cardiomyopathy, heart failure, and eventually death in many patients. Several etiologies are implicated in the development of myocarditis including autoimmune, drug-induced, infectious, and others. All causes lead to inflammation which causes damage to the myocardium followed by remodeling and fibrosis. This review aims to summarize recent findings in biomarkers for myocarditis and highlight the most promising candidates. Current methods of diagnosing myocarditis, including imaging and endomyocardial biopsy, are invasive, expensive, and often not done early enough to affect progression. Research is being done to find biomarkers of myocarditis that are cost-effective, accurate, and prognostically informative. These biomarkers would allow for earlier screening for myocarditis, as well as earlier treatment, and a better understanding of the disease course for specific patients. Early diagnosis of myocarditis with biomarkers may allow for prompt treatment to improve outcomes in patients.

Identifiants

pubmed: 35913661
doi: 10.1007/s11897-022-00569-8
pii: 10.1007/s11897-022-00569-8
pmc: PMC9340754
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

346-355

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL146754
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Abhilash Suresh (A)

Cleveland Clinic, Cleveland, OH, USA.

Pieter Martens (P)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA.

W H Wilson Tang (WHW)

Cleveland Clinic, Cleveland, OH, USA. tangw@ccf.org.
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA. tangw@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH